{"id":"albuterol-salbutamol-mdis","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"3-8","effect":"Nervousness/anxiety"},{"rate":"2-5","effect":"Palpitations"},{"rate":"2-5","effect":"Muscle cramps"},{"rate":"1-3","effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL714","moleculeType":"Small molecule","molecularWeight":"239.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Albuterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels. This leads to smooth muscle relaxation and airway dilation, providing rapid relief of bronchoconstriction. The metered-dose inhaler (MDI) formulation delivers the drug directly to the lungs for quick onset of action.","oneSentence":"Albuterol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing rapid relaxation and bronchodilation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:53.782Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute bronchospasm relief in asthma"},{"name":"Chronic obstructive pulmonary disease (COPD) symptom relief"},{"name":"Exercise-induced bronchoconstriction prevention"}]},"trialDetails":[{"nctId":"NCT06154304","phase":"PHASE3","title":"BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2023-12-06","conditions":"Bronchial Asthma","enrollment":120},{"nctId":"NCT04912596","phase":"NA","title":"Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma","status":"RECRUITING","sponsor":"Intech Biopharm Ltd.","startDate":"2022-08-15","conditions":"Mild Asthma","enrollment":148},{"nctId":"NCT04276233","phase":"PHASE4","title":"Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-06-29","conditions":"Asthma","enrollment":100},{"nctId":"NCT01899144","phase":"PHASE2","title":"Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07","conditions":"Asthma","enrollment":61},{"nctId":"NCT02584257","phase":"PHASE3","title":"Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma","status":"COMPLETED","sponsor":"Lupin, Inc.","startDate":"2016-04","conditions":"Mild Persistent Asthma","enrollment":217},{"nctId":"NCT02654145","phase":"PHASE4","title":"Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-17","conditions":"Asthma","enrollment":145},{"nctId":"NCT02624505","phase":"PHASE3","title":"Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2015-12","conditions":"Bronchial Asthma","enrollment":110},{"nctId":"NCT03376932","phase":"PHASE3","title":"Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-18","conditions":"Asthma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Albuterol/salbutamol MDIs","genericName":"Albuterol/salbutamol MDIs","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Albuterol is a beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing rapid relaxation and bronchodilation. Used for Acute bronchospasm relief in asthma, Chronic obstructive pulmonary disease (COPD) symptom relief, Exercise-induced bronchoconstriction prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}